导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.22% | 1424/4773 |
| 近一周 | -1.55% | 510/5462 |
| 近一月 | -3.66% | 1892/5421 |
| 近一季 | -7.14% | 2304/5209 |
| 近半年 | -1.25% | 1529/4920 |
| 近一年 | 7.78% | 1263/4366 |
| 近两年 | 56.35% | 1302/2954 |
| 近三年 | 40.38% | 712/2253 |
| 成立以来 | 163.25% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.02% 1671/4961 |
14.72% 1769/5312 |
- - |
- - |
| 2025 | 24.83% 1766/4813 |
-0.30% 2190/3635 |
3.97% 891/4076 |
17.37% 2520/4524 |
2.60% 902/4813 |
| 2024 | 14.88% 990/3463 |
3.90% 499/2808 |
-1.24% 997/3014 |
13.26% 2204/3129 |
-1.16% 1608/3463 |
| 2023 | -4.26% 671/2656 |
5.53% 778/2280 |
-2.71% 639/2385 |
-2.14% 623/2515 |
-4.71% 1150/2655 |
| 2022 | -14.82% 393/2207 |
-9.82% 354/1919 |
7.34% 493/2016 |
-11.98% 619/2113 |
-0.02% 1554/2208 |
| 2021 | 12.70% 378/1822 |
1.27% 259/1255 |
12.73% 314/1330 |
-0.11% 478/1466 |
-1.18% 1325/1822 |
| 2020 | 42.69% 259/1250 |
-4.23% 347/1028 |
17.26% 379/1067 |
13.20% 340/1164 |
12.25% 489/1184 |
| 2019 | 34.13% 414/1092 |
18.34% 643/739 |
-0.19% 225/788 |
3.53% 248/850 |
9.69% 208/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 富国MSCI中国A股国际通指数增强A VS. 长安沪深300非周期A(740101) |